Growth hormone and respiratory compromise in Prader-Willi Syndrome.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 16551791.
- Also identified by PMC identifier 2065960.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Recombinant human growth hormone (rhGH) therapy in Prader-Willi syndrome (PWS) causes increased basal metabolic rate and oxygen consumption, and hence increased ventilatory load. The case of an adolescent with PWS who experienced respiratory deterioration with an increase in rhGH and improvement with cessation of therapy is reported.
Medical subject headings
- Human Growth Hormone
- Prader-Willi Syndrome
- Respiratory Insufficiency